Nonprescription Drugs USA
|出版商||Kline & Company, Inc.||商品編碼||524958|
|出版日期||內容資訊||英文 936 Pages
A comprehensive analysis of the U.S. nonprescription drugs industry, focusing on key trends, developments, challenges, business opportunities, and new product activity, and offers insights and information on the following:
Features user-friendly database that is fully searchable and exportable that contains sales data, growth, share, and forecasts for hundreds of brands and companies across 30 categories. Through its alliance with IRI, Kline now includes as part this report, analysis of IRI MULO data for year ending 2016.
Nonprescription Drugs USA is an extensive industry resource used widely by marketing executives and other industry participants for competitive analysis, market investigation for new products, acquisition screening, and business planning. This report focuses solely on nonprescription drugs sold through domestic consumer outlets, including those marketed via drug stores, food stores, and mass merchandisers, in addition to nontraditional outlets such as health food stores, convenience stores, warehouse clubs, dollar stores, mail order, and the Internet. Market data refer exclusively to sales through these outlets. Direct and mail order sales are included, but sales to institutions such as hospitals and nursing homes and exports are excluded.
For more than 50 years, the study has proven to be the most authoritative and comprehensive annual source of information on the nonprescription drug industry. It contains industry trends and market size data for 31 product categories. In addition, market share and brand sales information are reported. The study profiles 11 leading major companies and approximately 50 minor companies. Included in the report is an analysis of regulatory developments, retail distribution, and private-label.
Subscribers to Nonprescription Drugs USA are afforded the following benefits:
An executive briefing covering developments in 2016, the impact of key trends and issues in the nonprescription drug business, and their future implications for industry participants. Includes analysis of retail distribution, private-label activity, and 5-year forecasts through 2021.
Pertinent information plus insightful analysis of 30 major categories, including key trends and developments; manufacturers' sales for 2015 and 2016, sales and market shares for leading brands, new product activity, sales by retail channel, private-label sales, marketing activity including traceable media expenditures, and outlook to 2021. The product categories covered are shown in Table 1.
Profiles of 11 major companies, including company activities; sales by product category and major brands in 2015 and 2016; recent developments including acquisitions, divestitures, and new products; corporate overview; and an outlook to 2021. The major companies covered are shown in Table 2.
Brief profiles of approximately 50 smaller OTC marketers, including corporate sales and profits, nonprescription drug sales for 2015 and 2016, recent developments including acquisitions, divestitures, new product activity, product portfolios, and traceable media expenditures for 2016.
* Subject to charter subscriber input